While one study found lower rates of preterm birth alongside higher rates of hypertensive disorders, another found fewer ...

GLP-1 Receptor Agonist Market. The global GLP-1 receptor agonist market is on the verge of unprecedented growth, fueled by ...

On his Instagram profile, the “Queer Eye” star Jonathan Van Ness detailed that he lost 30 kg with GLP-1 weight-loss ...

“The thing most amazing about them is how these drugs suddenly alter the dopamine-related reward pathway in the brain making us less of a slave to cravings. Today, 73% of Americans are obese or ...

A study comparing GLP-1 users to others on antidiabetic drugs showed no added risk once confounders were accounted for.

The Company granted Mr. Gengos a new hire option to purchase 750,000 shares of Terns common stock. The option has a 10-year term and an exercise price per share equal to $3.73, which was the closing ...

For individuals with type 2 diabetes (T2D), semaglutide is associated with a modestly increased risk for nonarterit ...

Obesity and diabetes have been two of the greatest public health challenges for decades. Many different diets and fads have promised the public ...

Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

Risk of suicidality wasn't higher for type 2 diabetes patients starting on GLP-1 receptor agonists than for those on two ...

The business of GLP-1s, it's mass adoption, compounded GLP-1s, compounding pharmacies, venture capital, and economic impact ...

Researchers investigating the role of the protein CD44 in obesity and metabolic health found that CD44-deficient mice stayed lean even on a high-fat diet, while the control mice developed obesity. A ...